#XFOR↓

XFOR/ 03/09/2026 · 10:56 AM

Buy Alert on XFOR: Guggenheim Highlights Mavorixafor as a Game-Changer in Rare Blood Disorders

Guggenheim starts coverage on X4 Pharmaceuticals with a Buy rating and $12 price target, highlighting major potential from mavorixafor in rare blood disorders like WHIM syndrome and chronic neutropenia.

XFOR/ 02/27/2026 · 7:30 AM

X4 Pharma’s Mavorixafor Wins Positive CHMP Opinion for WHIM Syndrome

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor, the potential first EU therapy for ultra-rare WHIM syndrome. EC decision expected Q2 2026.